Abstract
Spiropiperidine indoline-substituted diaryl ureas had been identified as antagonists of the P2Y1 receptor. Enhancements in potency were realized through the introduction of a 7-hydroxyl substitution on the spiropiperidinylindoline chemotype. SAR studies were conducted to improve PK and potency, resulting in the identification of compound 3e, a potent, orally bioavailable P2Y1 antagonist with a suitable PK profile in preclinical species. Compound 3e demonstrated a robust antithrombotic effect in vivo and improved bleeding risk profile compared to the P2Y12 antagonist clopidogrel in rat efficacy/bleeding models.
Keywords:
Antiplatelet agent; P2Y(1) antagonist; Spiropiperidinylindolines.
Copyright © 2014 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Animals
-
Dogs
-
Half-Life
-
Macaca fascicularis
-
Phenylurea Compounds / chemistry*
-
Phenylurea Compounds / pharmacokinetics
-
Phenylurea Compounds / pharmacology
-
Phenylurea Compounds / therapeutic use
-
Platelet Aggregation / drug effects
-
Platelet Aggregation Inhibitors / chemistry*
-
Platelet Aggregation Inhibitors / pharmacokinetics
-
Platelet Aggregation Inhibitors / pharmacology
-
Platelet Aggregation Inhibitors / therapeutic use
-
Purinergic P2Y Receptor Antagonists / chemistry*
-
Purinergic P2Y Receptor Antagonists / pharmacokinetics
-
Purinergic P2Y Receptor Antagonists / pharmacology
-
Purinergic P2Y Receptor Antagonists / therapeutic use
-
Rats
-
Receptors, Purinergic P2Y1 / chemistry*
-
Receptors, Purinergic P2Y1 / metabolism
-
Structure-Activity Relationship
-
Thiazoles / chemistry*
-
Thiazoles / pharmacokinetics
-
Thiazoles / pharmacology
-
Thiazoles / therapeutic use
-
Thrombosis / drug therapy
-
Urea / analogs & derivatives*
-
Urea / pharmacokinetics
-
Urea / pharmacology
-
Urea / therapeutic use
Substances
-
Phenylurea Compounds
-
Platelet Aggregation Inhibitors
-
Purinergic P2Y Receptor Antagonists
-
Receptors, Purinergic P2Y1
-
Thiazoles
-
Urea